Our interim results were harvested by the DSMC at mid term of the trial. They were complete and had a 28 day end point. That information was available before we completed the trial it would seem. Maybe the FDA based their decision on our first half of the phase 3 trial. Those results would show better since standard of care improved over the coarse of the trial the last 6 months.